GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

FDMT · Jun 30, 2026

4D Molecular Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001193125-26-349173General Corporate

Operating cash generation80thOwn-history percentile · N=10

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-1851.34% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

25106.67% · CORE · NOT_ENOUGH_HISTORY

Operating margin80thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.operating_margin

-2037.16% · CORE · VALID

SBC intensity30thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

155.62% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History7 statesHistory building

Dec 31, 20240/5 normalizedLevel 3 Mar 31, 20250/5 normalizedLevel 3 Jun 30, 20250/5 normalizedLevel 3 Sep 30, 20250/5 normalizedLevel 3 Dec 31, 20254/5 normalizedLevel 3 Mar 31, 20263/4 normalizedLevel 3 Jun 30, 20263/4 normalizedLevel 3

Period transition

What moved in the state?

Cash Generation Increased

Previous: -2235.81%
Current: -1851.34%
Delta: 384.47%

Growth Increased

Previous: 21664.29%
Current: 25106.67%
Delta: 3442.38%

Profitability Increased

Previous: -2416.15%
Current: -2037.16%
Delta: 378.99%

Sbc Intensity Increased

Previous: 146.14%
Current: 155.62%
Delta: 9.48%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Compared To · Biological Products, (No Diagnostic Substances) peers →Derived From · FDMT Company Quality Vector →Has State · 4D Molecular Therapeutics, Inc. →Transitioned To · FDMT Fundamental State →Transitioned To · FDMT CASH_GENERATION_INCREASED →Transitioned To · FDMT GROWTH_INCREASED →Transitioned To · FDMT PROFITABILITY_INCREASED →Transitioned To · FDMT SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.